Danica Pension Livsforsikringsaktieselskab Has $190.20 Million Stock Position in Boston Scientific Corporation $BSX

Key Points

• Danica Pension increased its stake in Boston Scientific by 12.1% to 1,994,729 shares — a position worth about $190.20 million, representing 0.13% of BSX and 2.7% of Danica's portfolio (its 11th largest holding).
• Near‑term sentiment is mixed: supportive catalysts include new clinical data favoring a Boston Scientific device and fresh hedge‑fund interest (Lone Pine/Jim Cramer commentary), while negatives include class‑action lawsuits, analyst downgrades and some fund selling that add legal and execution risk.
• Operationally BSX slightly beat Q1 estimates (EPS $0.80 vs $0.79) with revenue up 11.6%, and management guided Q2 EPS to $0.820–0.840 and FY2026 EPS to $3.340–3.410; the stock trades with a market cap around $85.7 billion and a P/E near 24.1.

Danica Pension Livsforsikringsaktieselskab boosted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 12.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,994,729 shares of the medical equipment provider's stock after buying an additional 215,837 shares during the period. Boston Scientific makes up 2.7% of Danica Pension Livsforsikringsaktieselskab's portfolio, making the stock its 11th largest holding. Danica Pension Livsforsikringsaktieselskab owned 0.13% of Boston Scientific worth $190,197,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Financial Consulate Inc. acquired a new position in Boston Scientific in the 3rd quarter valued at about $25,000. Murphy & Mullick Capital Management Corp grew its stake in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter valued at about $26,000. United Community Bank grew its stake in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 147 shares during the last quarter. Finally, Colonial Trust Co SC grew its stake in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 231 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: New clinical data and procedure adoption: A Reuters note highlighted that a procedure using a Boston Scientific device outperformed drug therapy for a heart‑rhythm indication, supporting device demand and reimbursement relevance. This is a clear product/market tailwind if adoption continues. Procedure using Boston Scientific device tops medication
• Positive Sentiment: Supportive TV commentary: Jim Cramer said he thinks Boston Scientific "can come back," a sentiment that can boost retail interest and short‑term buying flows. Jim Cramer on Boston Scientific
• Positive Sentiment: Institutional buying signal: Lone Pine Capital (Stephen Mandel) opened a new position, signaling selective hedge‑fund interest in BSX. Large manager activity can be supportive for the stock if it continues. Stephen Mandel opens new position
• Neutral Sentiment: Investor attention piece: Zacks flagged BSX as drawing investor attention, a sign of increased search/interest but not necessarily directional news. Monitor volume and follow‑through. Zacks: BSX attracting investor attention
• Neutral Sentiment: Ticker confusion: A GlobeNewswire item about Belo Sun TSX: BSX appears in feeds — note this is a different company and unrelated to Boston Scientific NYSE: BSX. Don’t conflate the two. Belo Sun Provides Update (unrelated ticker)
• Neutral Sentiment: Market commentary roundup: Aggregated articles (MSN/Yahoo) are weighing bullish vs bearish views; these are useful for sentiment tracking but contain no single material disclosure. MSN: Wall Street bullish or bearish?
• Negative Sentiment: Class‑action filings and lead‑plaintiff deadline (May 4): Multiple law firms and plaintiff notices allege disclosure issues around U.S. electrophysiology sales and invite claims—this increases legal overhang and potential settlement risk. Monitor filings and reserve/expense guidance. Securities fraud lawsuit alert
• Negative Sentiment: Analyst downgrades and lower targets: Daiwa cut BSX to "hold" and at least one outlet reports an ~11% cut to the price target — these reduce near‑term analyst support and can pressure sentiment. Daiwa downgrade / analyst action
• Negative Sentiment: Fund selling and estimate cuts: Polen Capital disclosed it sold its stake citing competition concerns, and Erste Group trimmed FY2026/27 EPS forecasts — both items point to investor wariness on competitive pressure and margin/earnings outlook. Polen sold stake

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company's stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company's stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.34% of the company's stock.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $57.69 on Friday. The company's 50 day moving average price is $67.06 and its two-hundred day moving average price is $84.72. Boston Scientific Corporation has a 12-month low of $56.05 and a 12-month high of $109.50. The firm has a market cap of $85.74 billion, a PE ratio of 24.14, a PEG ratio of 1.05 and a beta of 0.78. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the prior year, the firm posted $0.75 EPS. The firm's quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. TD Cowen decreased their price target on shares of Boston Scientific from $115.00 to $100.00 and set a "buy" rating on the stock in a research note on Monday, February 2nd. Wall Street Zen lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 28th. Citigroup decreased their target price on shares of Boston Scientific from $94.00 to $87.00 and set a "buy" rating on the stock in a research report on Tuesday, April 7th. Barclays decreased their target price on shares of Boston Scientific from $124.00 to $96.00 and set an "overweight" rating on the stock in a research report on Thursday, April 23rd. Finally, Jefferies Financial Group decreased their target price on shares of Boston Scientific from $110.00 to $100.00 and set a "buy" rating on the stock in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $93.91.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.